NCT07512154 Precision Radiotherapy Enabled by Molecular MRI
| NCT ID | NCT07512154 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
| Condition | Brain Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2026-04-29 |
| Primary Completion | 2031-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2026-04-29 with a primary completion date of 2031-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a research study to determine if a novel molecular magnetic resonance imaging (MRI) technique, called amide proton transfer (APT) imaging, is useful in identifying the most aggressive areas of tumor needed for radiotherapy of brain tumors.
Eligibility Criteria
Inclusion Criteria: * Histologic confirmation of glioblastoma or grade 4 astrocytoma * Age \>18 * KPS at least 60 * Patients must have normal organ and marrow function as defined below: * leukocytes \>3,000/mcL * absolute neutrophil count \>1,500/mcL * platelets \>100,000/mcL * total bilirubin within normal institutional limits * AST(SGOT)/ALT(SGPT) \<2.5 * institutional upper limit of normal * creatinine within normal institutional limits OR creatinine clearance \>60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal. * Patients of child-bearing potential (male or female) must practice adequate contraception due to possible harmful effects of radiation therapy on an unborn child. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Patients who are unable to receive MRIs will be excluded from the study. * Patients may not be receiving any other investigational cancer treatment agents at the time of enrollment. * Patients may not have previously been treated with an overlapping course of radiotherapy to the brain. * Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Pregnant and/or breastfeeding women are excluded. Women of child-bearing potential who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period and up to 12 weeks after the study are excluded. Male subjects must also agree to use effective contraception for the same period as above.
Contact & Investigator
Kristin Redmond
PRINCIPAL INVESTIGATOR
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Frequently Asked Questions
Who can join the NCT07512154 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Brain Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07512154 currently recruiting?
Yes, NCT07512154 is actively recruiting participants. Contact the research team at kjanson3@jhmi.edu for enrollment information.
Where is the NCT07512154 trial being conducted?
This trial is being conducted at Baltimore, United States.
Who is sponsoring the NCT07512154 clinical trial?
NCT07512154 is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The principal investigator is Kristin Redmond at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The trial plans to enroll 20 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.